List of Excipients in Branded Drug CAREONE DIARRHEA CONTROL

Generic Drugs Containing CAREONE DIARRHEA CONTROL

Company	Ingredient	NDC	Excipient
American Sales Company	loperamide hcl	41520-767	ANHYDROUS CITRIC ACID
American Sales Company	loperamide hcl	41520-767	CARBOXYMETHYLCELLULOSE SODIUM
American Sales Company	loperamide hcl	41520-767	CELLULOSE, MICROCRYSTALLINE
American Sales Company	loperamide hcl	41520-767	D&C YELLOW NO. 10

What are the Most Frequently-Used Excipients in CAREONE DIARRHEA CONTROL?

# Of NDCs	Excipient
2	ANHYDROUS CITRIC ACID
1	ANHYDROUS LACTOSE
2	CARBOXYMETHYLCELLULOSE SODIUM
1	CARNAUBA WAX

CareOne Diarrhea Control Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

CareOne Diarrhea Control is a private-label over-the-counter loperamide hydrochloride product, generally marketed at 2 mg per dosage unit for adults and children age 6 and older. Its commercial opportunity is primarily a cost-efficient, compliant, and differentiated dosage form rather than a new-chemical-entity or patent-exclusivity strategy. The strongest opportunities are rapid disintegration, easier swallowing, unit-dose packaging, shelf-stable formulations, and responsible use controls.

What drug is in CareOne Diarrhea Control?

CareOne Diarrhea Control is understood to contain loperamide hydrochloride, an opioid-receptor agonist acting primarily in the gut to reduce intestinal motility and increase transit time. U.S. OTC labeling generally identifies loperamide hydrochloride 2 mg as the active ingredient for temporary control of acute diarrhea [1].

Product attribute	Commercial assessment
Brand	CareOne
Product category	OTC antidiarrheal
Active ingredient	Loperamide hydrochloride
Typical strength	2 mg per caplet, tablet, or softgel
U.S. regulatory route	OTC monograph pathway
Reference brand	Imodium A-D
Primary buyers	Consumers, pharmacies, supermarkets, mass retailers
Primary competitor	Store-brand loperamide products
Biosimilar exposure	None
Orange Book relevance	Generally limited because the product is an OTC monograph drug
Main differentiation lever	Dosage form, excipients, packaging, price, and retailer placement

The product should be treated as a mature, multisource OTC drug. Its economics depend on manufacturing cost, retailer distribution, product availability, packaging efficiency, and consumer usability.

What excipients are likely used in CareOne Diarrhea Control?

The exact inactive-ingredient profile depends on the CareOne dosage form and current supplier specification. Conventional loperamide caplets commonly use excipients such as microcrystalline cellulose, starch or pregelatinized starch, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, and coating materials.

Typical excipient functions are as follows:

Excipient class	Function	Commercial relevance
Microcrystalline cellulose	Diluent and compression aid	Supports robust low-dose tablet manufacturing
Pregelatinized starch	Binder and disintegrant	Improves tablet strength and breakup
Croscarmellose sodium	Superdisintegrant	Supports rapid tablet disintegration
Crospovidone	Superdisintegrant	Alternative for faster breakup and lower swelling
Colloidal silicon dioxide	Glidant and moisture-control aid	Improves powder flow and manufacturing consistency
Magnesium stearate	Lubricant	Reduces tooling friction but can slow dissolution if overused
Film-coating polymer	Protection, appearance, swallowability	Enables color, branding, and moisture protection
Polyethylene glycol	Plasticizer or coating component	Improves coating flexibility
Titanium dioxide or approved colorants	Opacity and identification	Supports product differentiation
Mannitol or sorbitol	Diluent and mouthfeel modifier	Relevant to chewable or orally disintegrating formats
Flavoring agents	Taste masking	Required for chewable and orally disintegrating products

The key formulation issue is the low drug load. A 2 mg loperamide dose requires a tablet matrix that provides mechanical strength without delaying disintegration. Excipients therefore influence process capability, dissolution, dose uniformity, tablet size, and consumer acceptance more than they influence pharmacological performance.

What excipient strategy is best for a loperamide tablet?

A conventional immediate-release caplet should prioritize fast disintegration, low cost, moisture stability, and reliable compression. A practical formulation strategy would use a directly compressible diluent system combined with a superdisintegrant and a low-level lubricant.

Conventional caplet strategy

The most defensible baseline is:

• Microcrystalline cellulose or a co-processed cellulose-based diluent
• Pregelatinized starch or povidone as a binder
• Croscarmellose sodium or crospovidone as the primary disintegrant
• Colloidal silicon dioxide for flow
• Magnesium stearate at a controlled concentration
• A thin film coat for appearance and swallowability

This approach supports high-speed tableting and low unit cost. It also minimizes the regulatory and analytical burden associated with a new dosage form.

Magnesium stearate concentration and blending time require control. Excessive lubrication can reduce tablet tensile strength and slow wetting and dissolution. The formulation should be optimized against disintegration and dissolution targets rather than tablet hardness alone.

Moisture-control strategy

Loperamide products are typically distributed through retail channels with variable warehouse and household storage conditions. Moisture-resistant packaging can have greater commercial value than a complex excipient change.

Useful approaches include:

• Low-moisture excipient grades
• Film coatings with improved moisture barrier properties
• High-barrier blister packaging
• Desiccant-equipped bottles for larger-count formats
• Induction seals and child-resistant closures
• Reduced headspace in bottle configurations

A moisture-control strategy can reduce tablet softening, coating defects, dissolution drift, and stability failures. It also supports longer commercial shelf life without requiring an aggressive formulation redesign.

What dosage-form opportunities exist for CareOne Diarrhea Control?

Fast-disintegrating tablet

A fast-disintegrating tablet could provide a measurable consumer benefit without introducing the technical complexity of a true orally disintegrating tablet. Crospovidone, croscarmellose sodium, porous excipients, and optimized compression force can reduce breakup time.

The product would still require careful taste management because loperamide can produce an unpleasant mouthfeel. A film coating or taste-masking layer would be important.

Chewable tablet

A chewable version could target consumers who have difficulty swallowing caplets, travelers, and households seeking easier administration. Mannitol is a strong candidate because it provides cooling mouthfeel and supports compact chewable tablets. Sorbitol can improve sweetness but raises hygroscopicity and may affect stability.

The principal risks are:

• Bitterness and lingering aftertaste
• Excessive tablet friability
• Moisture uptake
• Sugar alcohol gastrointestinal effects
• Consumer confusion regarding dose limits

A chewable product should use prominent dosing instructions and should not be positioned as a pediatric product unless the labeling and clinical basis support that use.

Orally disintegrating tablet

An orally disintegrating tablet could command a higher retail price, but its commercial advantage over a standard caplet is uncertain. The format would require taste masking, low friability, packaging protection, and specialized manufacturing.

Alginates, ion-exchange resins, polymeric taste-masking systems, or coated drug particles could reduce bitterness. These systems increase formulation and process costs. For a low-priced private-label product, the margin case is strongest when the retailer can support premium placement or a travel-use positioning.

Softgel capsule

Softgels provide good swallowability and a familiar consumer format. They can support rapid drug release when the fill and shell system are properly designed. Their disadvantages are higher manufacturing cost, specialized equipment, shell moisture sensitivity, and more complex stability controls.

A softgel would compete directly with branded and store-brand loperamide softgels. It is more likely to support premium packaging than a major therapeutic advantage.

What FDA regulatory status applies to CareOne Diarrhea Control?

Loperamide hydrochloride is regulated in the United States as an OTC antidiarrheal under the FDA monograph framework. The relevant regulation is 21 C.F.R. Part 335, which addresses antidiarrheal products and includes loperamide-related conditions for use [2].

The commercial consequences are significant:

1. A compliant product does not depend on a new-drug application for routine monograph-conforming marketing.
2. Excipient changes remain subject to applicable drug-quality, labeling, manufacturing, and stability requirements.
3. New claims, new populations, or materially different dosing instructions can create a regulatory pathway outside the ordinary monograph strategy.
4. The product must comply with current good manufacturing practice requirements under 21 C.F.R. Parts 210 and 211 [3].
5. Packaging and labeling must address misuse, overdose, contraindications, and maximum daily dosing.

Loperamide has attracted FDA safety communications because excessive doses can cause severe cardiac events, including QT prolongation, torsades de pointes, syncope, and cardiac arrest [4]. An excipient strategy should not increase systemic exposure or encourage excessive dosing.

What is the Orange Book status of CareOne Diarrhea Control?

CareOne Diarrhea Control is generally not an Orange Book-centered product. The Orange Book primarily identifies approved prescription drugs, approved drug applications, therapeutic equivalence evaluations, and listed patents or exclusivity information associated with approved applications [5].

For a monograph OTC drug:

• Orange Book-listed patent barriers are generally not the main market-access issue.
• Paragraph IV litigation is usually not the relevant competitive mechanism.
• There is no conventional Hatch-Waxman generic launch sequence comparable to a patented prescription product.
• Market entry is driven by monograph compliance, manufacturing capability, retailer authorization, labeling, and supply economics.

The absence of a meaningful Orange Book patent barrier does not eliminate commercial risk. Retailer contracts, private-label sourcing decisions, quality audits, recalls, and pricing pressure are more relevant.

When does loperamide lose exclusivity?

Loperamide has long been available as a generic and OTC active ingredient. The active ingredient does not present a current composition-of-matter exclusivity opportunity for CareOne.

Exclusivity category	Current relevance
New chemical entity exclusivity	None of practical relevance
Composition-of-matter patent	Not a meaningful barrier for standard loperamide products
Prescription drug exclusivity	Not the principal market structure
OTC monograph access	The central regulatory pathway
Formulation patent	Potentially relevant only for a novel, non-obvious dosage form
Method-of-use patent	Limited value for standard antidiarrheal labeling
Manufacturing patent	Potentially relevant for specialized processes, but difficult to enforce against ordinary products

A new excipient system could support patent claims only if it produces a technically meaningful and non-obvious result, such as improved stability, taste masking, rapid disintegration under defined conditions, or a distinct controlled-release profile. Routine substitution of one standard filler or disintegrant for another is unlikely to create strong enforceable protection.

What formulation patents could protect a CareOne line extension?

The strongest patent candidates would relate to a defined formulation architecture rather than the use of a conventional excipient in isolation.

Potential claim areas include:

Taste-masked loperamide

Claims could cover coated loperamide particles, polymeric barriers, ion-exchange complexes, or multiparticulate systems that reduce bitterness while preserving immediate release.

Commercial value would depend on:

• Measurable taste improvement
• A repeatable particle-coating process
• Acceptable dissolution after ingestion
• Lower excipient loading
• Suitability for chewable or orally disintegrating products

Rapid-disintegration system

A patent position could focus on a specific ratio of disintegrants, porous carrier, compression profile, or tablet structure that produces rapid breakup without excessive friability.

A generic claim to "a tablet containing loperamide and a superdisintegrant" would likely be weak because the components are conventional.

Moisture-stable dosage form

A formulation or package combination could be protectable if it demonstrates unexpected stability under accelerated conditions. The commercial protection may come from a combination of formulation claims, packaging claims, and manufacturing controls.

Multiparticulate capsule

Pellets or coated granules could support a premium product with rapid release, improved dose uniformity, or reduced mouth bitterness. The cost structure is less attractive for a value-oriented private label unless the format supports a meaningful retail premium.

What generic entry risks exist for CareOne Diarrhea Control?

Generic entry risk is high because standard loperamide products are mature and widely available. The principal risk is not a single Paragraph IV challenger. It is substitution by competing store brands and contract manufacturers.

The main competitive pressures are:

• Lower-cost loperamide caplets
• Private-label softgels
• Pharmacy-brand products
• Branded Imodium A-D products
• Travel-size packages
• Multi-count value bottles
• Rapid-dissolving or chewable line extensions

CareOne can reduce direct price comparison through dosage-form differentiation, but a premium format must justify higher manufacturing and packaging costs. A simple caplet has the best cost position, while an orally disintegrating or chewable product has greater differentiation but narrower margins.

Which companies are competing with CareOne Diarrhea Control?

The relevant competitors include Johnson & Johnson consumer-health brands associated with Imodium, retailer private labels, generic OTC manufacturers, and contract manufacturers supplying pharmacy and supermarket brands.

Competitor type	Competitive advantage
Imodium A-D	Brand recognition, broad distribution, consumer trust
Pharmacy private labels	Pharmacist access and price
Supermarket private labels	Retailer control and low shelf price
Mass-retail private labels	Scale, high traffic, value positioning
Generic OTC manufacturers	Manufacturing cost and sourcing flexibility
Travel-health brands	Portable packaging and use-case positioning

CareOne's most important advantage is likely retail distribution through the associated grocery and pharmacy network rather than proprietary product technology.

What commercial opportunities exist for excipient innovation?

Premium travel format

A small-count, moisture-protected pack with a fast-disintegrating or easy-swallow tablet could target travelers. A high-barrier blister can improve portability and dosing control.

Swallowability platform

A smooth film-coated caplet or softgel can target adults who avoid large tablets. This is a broad consumer benefit and can be implemented without major therapeutic changes.

Taste-masked chewable

A chewable product could expand use among consumers who prefer non-swallow formats. The principal value is convenience, not faster pharmacological action.

Retailer-exclusive configurations

Count size, blister format, bottle design, and multipack architecture can create retailer-specific products without relying on a novel active ingredient. These changes can support differentiated shelf placement and reduce direct unit-price comparison.

Accessible product design

Large-print labels, easy-open but child-resistant packaging, and clearly separated dosing instructions can improve use by older consumers. These design changes do not require a new excipient system but can strengthen commercial positioning.

How does CareOne compare with Imodium A-D?

Factor	CareOne Diarrhea Control	Imodium A-D
Active ingredient	Loperamide hydrochloride	Loperamide hydrochloride
Core therapeutic role	Temporary diarrhea control	Temporary diarrhea control
Patent advantage	None apparent for standard product	Brand and formulation differentiation may support pricing
Main advantage	Lower price and retailer access	Brand recognition
Formulation opportunity	Private-label line extensions	Premium dosage forms and brand extensions
Consumer acquisition	Retail shelf and price	Brand demand and marketing
Key risk	Commoditization	Price competition from store brands

For standard caplets, the products are likely therapeutically substitutable when they contain the same active ingredient and conform to the same labeling. CareOne's commercial case therefore depends on price, availability, packaging, and retailer strategy.

What patent litigation and settlement issues affect loperamide?

No major current Paragraph IV litigation or settlement structure is central to standard OTC loperamide caplets. The product category is mature, monograph-based, and broadly commoditized.

Potential disputes would more likely involve:

• Trade dress
• Trademark use
• Package design
• Product liability
• Manufacturing quality
• Labeling compliance
• Formulation patents for specialized dosage forms
• Contract disputes between retailers and suppliers

A new formulation patent could create litigation exposure if it covers a premium loperamide dosage form. Standard excipient substitutions are less likely to generate meaningful patent disputes.

What is the revenue exposure for CareOne Diarrhea Control?

CareOne product-level revenue is not typically disclosed separately by the retailer. The commercial exposure can be assessed through category economics rather than reported product sales.

Revenue drivers include:

• Store penetration
• Unit velocity
• Seasonal diarrhea incidence
• Travel demand
• Count size
• Private-label price discount
• Gross margin per package
• Retailer promotional support
• Supply continuity

A conventional bottle or caplet has the broadest distribution potential but faces strong price erosion. A differentiated blister, chewable, or fast-disintegrating format may produce higher gross profit per package, although volume could be lower.

How strong is the patent estate for CareOne Diarrhea Control?

The patent estate for a standard CareOne loperamide product is weak or nonexistent as a barrier to competition. The active ingredient is mature, standard excipients are widely known, and the regulatory pathway is based on OTC monograph compliance.

Patent strength could improve only through:

1. A demonstrably novel taste-masking system.
2. A specific rapid-disintegration architecture.
3. A validated stability-enhancing formulation.
4. A proprietary multiparticulate or softgel manufacturing process.
5. A package-formulation combination that produces an unexpected shelf-life result.

Even then, freedom-to-operate analysis would need to cover excipient suppliers, coating technologies, capsule technologies, packaging patents, and competing OTC products.

Key Takeaways

• CareOne Diarrhea Control is a mature loperamide hydrochloride OTC product with limited conventional exclusivity value.
• Excipient selection should prioritize rapid disintegration, mechanical strength, taste control, moisture stability, and low manufacturing cost.
• The strongest commercial opportunities are fast-disintegrating tablets, chewables, softgels, travel blisters, and moisture-resistant packaging.
• A standard formulation has little patent leverage. A novel taste-masking, stability, or multiparticulate system could support narrower formulation protection.
• Paragraph IV litigation, biosimilar competition, and Orange Book patent barriers are not central to the product category.
• FDA safety controls are commercially important because excessive loperamide dosing can cause serious cardiac events.
• CareOne competes mainly through retailer access, price, private-label economics, and product availability.
• Product-level revenue is not publicly isolated, so opportunity assessment should focus on margin, shelf placement, package count, and category velocity.

FAQs

Is CareOne Diarrhea Control the same as Imodium?

Both products generally use loperamide hydrochloride as the active ingredient, but inactive ingredients, dosage forms, packaging, labeling presentation, and price may differ.

Can a loperamide chewable tablet be patented?

A chewable tablet can be patentable if it uses a novel and non-obvious formulation or manufacturing system. A routine combination of loperamide, mannitol, flavor, and a conventional disintegrant would provide limited patent strength.

Does CareOne Diarrhea Control have biosimilar risk?

No. Biosimilar competition applies to biological products. Loperamide hydrochloride is a small-molecule drug.

What excipient is most important for rapid loperamide tablet breakup?

Croscarmellose sodium or crospovidone is typically central to rapid disintegration, but performance depends on the complete formulation, compression force, lubricant level, and tablet porosity.

Is a softgel commercially superior to a loperamide caplet?

Not automatically. A softgel may improve swallowability and support premium positioning, but it generally has higher manufacturing, packaging, and stability costs than a conventional caplet.

References

1. U.S. Food and Drug Administration. (2024). Drug facts label: Loperamide hydrochloride 2 mg antidiarrheal products. FDA.
2. Code of Federal Regulations. (2024). 21 C.F.R. Part 335: Antidiarrheal drug products for over-the-counter human use.
3. Code of Federal Regulations. (2024). 21 C.F.R. Parts 210-211: Current good manufacturing practice in manufacturing, processing, packing, or holding of drugs.
4. U.S. Food and Drug Administration. (2016). FDA warns about serious heart problems with high doses of the anti-diarrheal medicine loperamide, including abuse and misuse. FDA Drug Safety Communication.
5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. 44th ed. FDA.